Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | B7-H3 CAR-T cells |
| Synonyms | |
| Therapy Description |
B7-H3 CAR-T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting B7-H3 (CD276), which potentially inhibit growth of B7-H3-positive tumors (Cancer Res (2023) 83 (7_Supplement): 1197). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| B7-H3 CAR-T cells | B7H3-CAR T|B7-H3CART | CD276 Immune Cell Therapy 10 | B7-H3 CAR-T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting B7-H3 (CD276), which potentially inhibit growth of B7-H3-positive tumors (Cancer Res (2023) 83 (7_Supplement): 1197). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07222735 | Phase I | Cyclophosphamide + Fludarabine B7-H3 CAR-T cells | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | Recruiting | USA | 0 |
| NCT05835687 | Phase I | B7-H3 CAR-T cells | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | Recruiting | USA | 0 |